Search

Your search keyword '"Uy, Geoffrey L."' showing total 5 results
Start Over Author "Uy, Geoffrey L." Database OpenAIRE
5 results on '"Uy, Geoffrey L."'

2. Junior investigators: Get engaged in the Alliance for Clinical Trials in Oncology

Author

Uy, Geoffrey L., Katz, Matthew H. G., and Boughey, Judy C.

Subjects
Clinical Trials as Topic, Biomedical Research, Surgical Oncology, Humans, Article, United States
Abstract

The success of the Alliance and the cooperative groups in the National Cancer Institute's National Clinical Trials Network is dependent on the cooperative group's ability to help recruit and train the next generation of clinical researchers.

Published
2017

3. Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis

Author

Deol, Abhinav, Sengsayadeth, Salyka, Ahn, Kwang Woo, Wang, Hai-Lin, Aljurf, Mahmoud D., Antin, Joseph Harry, Battiwalla, Minoo, Bornhauser, Martin, Cahn, Jean-Yves, Camitta, Bruce M., Chen, Yi-Bin, Cutler, Corey S., Gale, Robert Peter, Ganguly, Siddhartha, Hamadani, Mehdi, Inamoto, Yoshihiro, Jagasia, Madan H., Kamble, Rammurti T., Koreth, John, Lazarus, Hillard M., Liesveld, Jane L., Litzow, Mark R., Marks, David I., Nishihori, Taiga, Olsson, Richard F., Reshef, Ran, Rowe, Jacob M., Saad, Ayman, Sabloff, Mitchell, Schouten, Hendricus, Shea, Thomas C., Soiffer, Robert J., Uy, Geoffrey L., Waller, Edmond K, Wiernik, Peter H., Wirk, Baldeep M., Woolfrey, Ann E., Bunjes, Donald, Devine, Steven M., de Lima, Marcos J., Sandmaier, Brenda M, Weisdorf, Dan, Khoury, Hanna Jean, Saber, Wael, Interne Geneeskunde, MUMC+: MA Hematologie (9), and RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy

Subjects
Adult, Male, Adolescent, TANDEM DUPLICATIONS, 1 more, MINIMAL RESIDUAL DISEASE, DISTINCT, COMPLETE REMISSION, acute myeloid leukemia, Article, Young Adult, fluids and secretions, AML, allogeneic stem cell transplantation, hemic and lymphatic diseases, Journal Article, 12 TRIALS, Humans, ALLOGENEIC TRANSPLANTATION, Survivors, Neoplasm Staging, FMS-like tyrosine kinase 3 (FLT3), Hematopoietic Stem Cell Transplantation, hemic and immune systems, Middle Aged, Allografts, Prognosis, CYTOGENETICS, GENE, Survival Rate, Leukemia, Myeloid, Acute, fms-Like Tyrosine Kinase 3, embryonic structures, Mutation, Female, Follow-Up Studies
Abstract

BACKGROUND: Patients with FMS like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukemia (AML) have a poor prognosis and are referred for early allogeneic hematopoietic stem cell transplantation (HCT). METHODS: Data from the Center for International Blood and Marrow Transplant Research (CIBMTR) were used to evaluate 511 adult patients with de novo AML who underwent HCT during 2008 through 2011 to determine whether FLT3 mutations had an impact on HCT outcomes. RESULTS: In total, 158 patients (31%) had FLT3 mutations. Univariate and multivariate analyses revealed an increased risk of relapse at 3 years in the FLT3 mutated group compared with the wild-type (WT) group (38% [95% confidence interval (CI), 30%-45%] vs 28% [95% CI, 24%-33%]; P = .04; relative risk, 1.60 [95% CI, 1.15-2.22]; P = .0048). However, FLT3 mutation status was not significantly associated with nonrelapse mortality, leukemia-free survival, or overall survival. Although more patients in the FLT3 mutated group died from relapsed primary disease compared with those in the WT group (60% vs 46%), the 3-year overall survival rate was comparable for the 2 groups (mutated group: 49%; 95% CI, 40%-57%; WT group: 55%, 95% CI, 50%-60%; P = .20). CONCLUSIONS: The current data indicate that FLT3 mutation status did not adversely impact overall survival after HCT, and about 50% of patients with this mutation who underwent HCT were long-term survivors. Cancer 2016;122:3005-3014. © 2016 American Cancer Society.

Published
2016

4. Phase I Study of Oral Clofarabine Consolidation in Adults Aged 60 and Older with Acute Myeloid Leukemia

Author

Jacoby, Meagan A., Martin, Michael G., Uy, Geoffrey L., Westervelt, Peter, DiPersio, John F., Cashen, Amanda, Stockerl-Goldstein, Keith, Vij, Ravi, Luo, Jingqin, Reineck, Teresa, Bernabe, Noel, and Abboud, Camille N.

Subjects
Male, Antimetabolites, Antineoplastic, Dose-Response Relationship, Drug, Adenine Nucleotides, Administration, Oral, Middle Aged, Article, Cohort Studies, Consolidation Chemotherapy, Leukemia, Myeloid, Acute, Humans, Female, Arabinonucleosides, Aged, Clofarabine
Abstract

Clofarabine has shown activity and tolerability in older patients with acute myeloid leukemia (AML). We investigated the safety and tolerability of an oral formulation of clofarabine for consolidation therapy of patients aged 60 and older with AML. In this phase I study, twenty-two patients older than 60 years with AML in first complete remission were treated once daily with oral clofarabine for 14 or 21 days of a 28-day cycle, for up to five cycles. Dose escalation from 1 mg to 6 mg daily using a 3 + 3 design was used to determine dose-limiting toxicities (DLT), the maximum tolerated dose (MTD), and tolerability of oral clofarabine. No DLTs or Grade 3-4 nonhematologic toxicities were observed. The primary toxicities were hematologic, including uncomplicated grade 3-4 neutropenia (50%) and thrombocytopenia (50%). Given that myelosuppression necessitating dose delays/reductions was observed more commonly at higher doses, the recommended phase II dose is 2 mg daily for 21 of 28 days. At doses equal to or greater than 2 mg, the median relapse-free survival was 28.35 months. Oral clofarabine was well-tolerated with encouraging activity in patients older than 60 years. Further investigation of oral clofarabine as a consolidation and/or maintenance therapy in AML for older individuals is warranted. (ClinicalTrials.gov:NCT00727766).

Published
2014

5. Flotetuzumab as Salvage Immunotherapy for Refractory Acute Myeloid Leukemia

Author

Martha Arellano, Patrick J. Stiff, Geoffrey L. Uy, Sarah E. Church, Norbert Vey, Marianne Santaguida, Patrick Kaminker, Ibrahim Aldoss, Erin Fehr, Michael P. Rettig, Matthew C. Foster, Maya Kostova, Patrice Chevallier, John F. DiPersio, Peter H. Sayre, Anjali S. Advani, Erica K. Anderson, Kendra Sweet, Bob Löwenberg, Matthew J. Wieduwilt, Martin Wermke, Farhad Ravandi, Jayakumar Vadakekolathu, Ezio Bonvini, Michael Byrne, Mojca Jongen-Lavrencic, Emmanuel Gyan, Matteo Carrabba, Jan K Davidson-Moncada, John E. Godwin, Laura C. Michaelis, Gerwin Huls, Fabio Ciceri, Kenneth Jacobs, Sergio Rutella, Ouiam Bakkacha, Kristen Pettit, Christian Recher, Kathy M. Tran, Teia Curtis, Stefania Paolini, Jian Zhao, Roland B. Walter, Max S. Topp, Kuo Guo, Ashkan Emadi, John Muth, Harry P. Erba, Uy, Geoffrey L, Aldoss, Ibrahim, Foster, Matthew C, Sayre, Peter H, Wieduwilt, Matthew J, Advani, Anjali S, Godwin, John E, Arellano, Martha L, Sweet, Kendra, Emadi, Ashkan, Ravandi, Farhad, Erba, Harry P, Byrne, Michael, Michaelis, Laura C, Topp, Max S, Vey, Norbert, Ciceri, Fabio, Carrabba, Matteo Giovanni, Paolini, Stefania, Huls, Gerwin, Jongen-Lavrencic, Mojca, Wermke, Martin, Chevallier, Patrice, Gyan, Emmanuel, Récher, Christian, Stiff, Patrick, Pettit, Kristen, Löwenberg, Bob, Church, Sarah, Anderson, Erica Katherine, Vadakekolathu, Jayakumar, Santaguida, Marianne T, Rettig, Michael P, Muth, John, Curtis, Teia, Fehr, Erin, Guo, Kuo, Zhao, Jian, Bakkacha, Ouiam, Jacobs, Kenneth, Tran, Kathy, Kaminker, Patrick, Kostova, Maya, Bonvini, Ezio, Walter, Roland B, Davidson-Moncada, Jan Kenneth, Rutella, Sergio, Dipersio, John F, Hematology, Stem Cell Aging Leukemia and Lymphoma (SALL), and Guided Treatment in Optimal Selected Cancer Patients (GUTS)

Subjects
Male, Myeloid, Clinical Trials and Observations, Salvage therapy, Biochemistry, Gastroenterology, RECOMMENDATIONS, Antineoplastic Agents, Immunological, hemic and lymphatic diseases, Antineoplastic Combined Chemotherapy Protocols, Antibodies, Bispecific, CRITERIA, Protein Interaction Maps, MYELODYSPLASTIC SYNDROME, Aged, 80 and over, RECEPTOR T-CELLS, Myeloid leukemia, Nausea, Hematology, Middle Aged, Fludarabine, CYTARABINE, Survival Rate, Leukemia, Myeloid, Acute, Cytokine release syndrome, Leukemia, medicine.anatomical_structure, PHASE-II, Female, Immunotherapy, FLUDARABINE, medicine.drug, Adult, medicine.medical_specialty, Maximum Tolerated Dose, Immunology, Dose-Response Relationship, Immunologic, Antibodies, Monoclonal, Humanized, DIAGNOSIS, Drug Administration Schedule, Internal medicine, medicine, Humans, Immunologic Factors, neoplasms, Survival rate, Aged, Salvage Therapy, business.industry, CYTOKINE RELEASE SYNDROME, Cell Biology, medicine.disease, Hematopoiesis, Drug Resistance, Neoplasm, Cytarabine, BLINATUMOMAB, business, Follow-Up Studies
Abstract

Approximately 50% of acute myeloid leukemia (AML) patients do not respond to induction therapy (primary induction failure [PIF]) or relapse after

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results